Losartan potassium and Ocular hyperaemia - a phase IV clinical study of FDA data

Summary:

Ocular hyperaemia is reported as a side effect among people who take Losartan potassium (losartan potassium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Oxervate, and have Neurotrophic keratopathy.

The phase IV clinical study analyzes which people have Ocular hyperaemia when taking Losartan potassium. It is created by eHealthMe based on reports of 50,026 people who have side effects when taking Losartan potassium from the FDA, and is updated regularly.

What is Losartan potassium?

Losartan potassium has active ingredients of losartan potassium. It is often used in high blood pressure. eHealthMe is studying from 51,511 Losartan potassium users. Check the latest studies of Losartan potassium.

What is Ocular hyperaemia?

Ocular hyperaemia (an abnormally large amount of blood in eye) is found to be associated with 1,357 drugs and 1,499 conditions by eHealthMe. Check the latest studies of Ocular hyperaemia.

On Jul, 13, 2026

50,026 people reported to have side effects when taking Losartan potassium.
Among them, 182 people (0.36%) have Ocular hyperaemia.

Could Losartan potassium cause Ocular hyperaemia?

Among these 182 people:

How long have people been on Losartan potassium when they have Ocular hyperaemia? *

Click here to view more results

What is the gender of people who have Ocular hyperaemia when taking Losartan potassium? *

Click here to view

What is the age of people who have Ocular hyperaemia when taking Losartan potassium? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Losartan potassium and have Ocular hyperaemia?

- Check whether Ocular hyperaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Losartan potassium:

Losartan potassium (51,511 reports)

Ocular hyperaemia treatments and more:

Ocular hyperaemia (47,107 reports)

How severe was Ocular hyperaemia and when was it recovered:

Ocular hyperaemia in Losartan potassium

Expand to all the drugs that have ingredients of losartan potassium:

Ocular hyperaemia and drugs with ingredients of losartan potassium (659 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Losartan potassium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,357 drugs)

Browse all the conditions that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,499 conditions)

Related publications that referenced our studies

Lai SW, Lin HF, Lin CL, Liao KF, "No association between losartan use and acute pancreatitis in hypertensive patients", Eur J Hosp Pharm, 2017 Mar .
Lai SW, Lin HF, Lin CL, Liao KF, "No association between losartan use and acute pancreatitis in hypertensive patients", Eur J Hosp Pharm, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on losartan potassium (the active ingredients of Losartan potassium) and Losartan potassium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.